Search

Your search keyword '"Heart Failure With Preserved Ejection Fraction"' showing total 9,951 results

Search Constraints

Start Over You searched for: Descriptor "Heart Failure With Preserved Ejection Fraction" Remove constraint Descriptor: "Heart Failure With Preserved Ejection Fraction"
9,951 results on '"Heart Failure With Preserved Ejection Fraction"'

Search Results

1. Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF.

2. Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study.

3. J-shaped association between serum glucose potassium ratio and prognosis in heart failure with preserved ejection fraction with stronger predictive value in non-diabetic patients.

4. Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review.

5. Lower heart rate in patients with acute heart failure: the role of left ventricular ejection fraction.

6. Characterizing heart failure and its subtypes in people living with HIV.

7. A non-invasive nomogram for predicting heart failure with preserved ejection fraction in taiwanese outpatients with unexplained dyspnea and fatigue.

8. First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.

9. Prediction of 90 day readmission in heart failure with preserved ejection fraction by interpretable machine learning.

10. Immune cell profiling of the ICAM1 p.K56M heart failure with preserved ejection fraction risk variant.

11. IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction.

12. Rates and predictors of cardiovascular and non‐cardiovascular outcomes in heart failure with preserved ejection fraction.

13. Heart Failure in Rheumatoid Arthritis: Clinical Implications.

14. Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure.

16. Prognostic effects of glycaemic variability on diastolic heart failure and type 2 diabetes mellitus: insights and 1-year mortality machine learning prediction model.

17. Triglyceride-glucose index is associated with heart failure with preserved ejection fraction in different metabolic states in patients with coronary heart disease.

18. Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?

19. Follow‐Up Study of Percutaneous Intramyocardial Septal Radiofrequency Ablation in the Treatment of Hypertrophic Obstructive Cardiomyopathy With HFpEF.

20. Integrated biomarker profiling for enhanced heart failure management: a comprehensive study on the application of chemiluminescence detection of GDF-15 and multi-index models.

21. Native skeletal muscle T1-time on cardiac magnetic resonance: A predictor of outcome in patients with heart failure with preserved ejection fraction.

22. Hospitalization after hydroxychloroquine initiation in patients with heart failure with preserved ejection fraction and autoimmune disease.

23. Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction.

24. Role of NLRP3 Inflammasome in Heart Failure Patients Undergoing Cardiac Surgery as a Potential Determinant of Postoperative Atrial Fibrillation and Remodeling: Is SGLT2 Cotransporter Inhibition an Alternative for Cardioprotection?

25. CMR to characterize myocardial structure and function in heart failure with preserved left ventricular ejection fraction.

26. Contemporary treatment options in heart failure with preserved ejection fraction.

27. Diastolic dysfunction in hypertension: a comprehensive review of pathophysiology, diagnosis, and treatment.

28. Imaging and mechanisms of heart failure with preserved ejection fraction: a state-of-the-art review.

29. Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.

30. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.

31. Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure.

32. Heart Failure and Obesity: Unraveling Molecular Mechanisms of Excess Adipose Tissue.

33. Cardiac structural and functional changes in OSAHS patients with heart failure with preserved ejection fraction and atrial fibrillation.

34. 射血分数保留型心力衰竭患者心率变异性与 左心室僵硬度的相关性.

35. 基于NLRP3/caspase-1/GSDMD 信号通路探讨 双硫仑改善HFpEF 大鼠心功能的机制.

36. 'Working me to life': longitudinal perceptions from adults with heart failure with preserved ejection fraction enrolled in an exercise training clinical trial.

37. Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score.

38. Catheter‐based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA‐HFPEF‐DZHK27 trial.

39. 血清sTWEAK、sLOX-1 与H型高血压合并 HFpEF 患者颈动脉粥样硬化的关系.

40. T细胞亚群在射血分数保留的心力衰竭中的研究进展.

41. Assessing Static Balance, Balance Confidence, and Fall Rate in Patients with Heart Failure and Preserved Ejection Fraction: A Comprehensive Analysis.

42. Leukocyte Indices as Markers of Inflammation and Predictors of Outcome in Heart Failure with Preserved Ejection Fraction.

43. Cardiac remodeling: novel pathophysiological mechanisms and therapeutic strategies.

44. Association between triglyceride glycemic index and ejection fraction preserved heart failure in hypertensive patients.

45. Sex-specific cardiovascular remodeling leads to a divergent sex-dependent development of heart failure in aged hypertensive rats.

46. Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT‐HFpEF registry.

47. Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction.

48. Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction.

49. Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction.

50. Rates and predictors of cardiovascular and non‐cardiovascular outcomes in heart failure with preserved ejection fraction

Catalog

Books, media, physical & digital resources